Unilife — Q1 FY2014 Earnings Presentation
9 slides from Unilife's earnings presentation, Nov 12, 2013
Slide 1: Fiscal Year 2014 First Quarter Earnings Call
Exhibit 99.2 st Fiscal Year 2014 Quarter 1 Earnings Call November 11, 2013 1
Slide 2: Cautionary Note Regarding Forward-Looking Statements
CautionaryNoteRegarding Forward-Looking Statements Thispresentationcontainsforward lookingstatementsunder the safeharbor provisionsof the USsecuritieslaws.Theseforward-lookingstatementsarebased on management’sbeliefsand assumptionsand on informationcurrently availableto our management. Ourmanagement
Slide 3: Introductory Comments by Unilife CEO Alan Shortall
Introductory Comments by Unilife CEO Alan Shortall Entered period of long-term partnerships and rapid revenue growth Received $5MM Sanofi payment (deferred revenue in Sep 30, 2013 balance sheet) Beginning to receive payments from other customers for active programs Sequential quarterly growth antici
Slide 4: The Market for Wearable Injectors
The Market for Wearable Injectors Estimated 350 million wearable injectors to be sold annually by 2024 $20 -$35 ASP /unit likely to translate into a market size of $8.8 billion by 2024 Projected CAGR of 138% from 2015 2020 - and 48% from 2020 – 2024 More than 110 high viscous and large volume market
Slide 5: ReadyToGo Platform of Wearable Injectors
ReadyToGo™ Platform of Wearable Injectors Pre-Filled. Pre-Assembled. Ready-to-Inject. Precision-Therapy™ Flex-Therapy™ For long-duration therapies that requireFor long-duration therapies that require delivery of delivery of large dose volumes large dose volumes with a specific rate profile 5
Slide 6: Supply Contract with MedImmune
Supply Contract with MedImmune MedImmune is the global biologics R&D arm of AstraZeneca One of the richest biologic portfolios in the industry 120 large molecule drugs in R&D (half of AstraZeneca’s total clinical pipeline) Under this agreement, Unilife will customize and supply devicesfrom its platf
Slide 7: Financial Data
Financial Data 1Q FY2014 1Q FY2013 Revenues $3.2MM $0.7MM Research & development $6.4MM $4.7MM Selling, general & administrative $6.5MM $6.6MM Net loss $11.2MM $12.5MM Net loss per share d–iluted $0.12 $0.16 Adjusted net loss $7.1MM $9.1MM Adjusted net loss per sharediluted - $0.08 $0.12 7
Slide 8: Moving Forward
Moving Forward Focused on rapid and significant growth in the long-term Anticipating sequential quarterly growth in FY2014 Annual growth year over prior year in FY2014 and beyond Continuing to increase investment in R&D and operations Much of our operating expenditure to be offset by increasing reve
Slide 9: Questions
Fiscal Year 2014 1 Quarter st Earnings Call Questions 9